Merck Ventures

BV, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany

“Our investments will be aligned with the strategic interests of Merck KGaA, Darmstadt, Germany, though formally separated by a ‘Chinese Wall’. With our infrastructure of a leading science technology company we provide start-ups with the support they need to make their vision a commercial success.”

Roel Bulthuis
Senior Vice President and Managing Director of Merck Ventures BV, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany

More

2016/06/08

Merck KGaA, Darmstadt, Germany, Expands its Corporate Ventures Fund

Darmstadt, Germany, June 8, 2016 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced an increased commitment to its Corporate Ventures fund under the new Corporate Ventures fund roof (official name: Merck Ventures BV, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany). Four dedicated investment teams will focus on Healthcare, Life Science, Performance Materials and new businesses. The total volume of the newly set-up Corporate Ventures fund of Merck KGaA, Darmstadt, Germany, can reach up to € 300 million once fully invested, doubling the volume of the previous biopharma venture fund of € 150 million.

more

Upcoming Events

2017/10/03

SynBioBeta San Francisco 2017

Andreas Jurgeit, Ivestment Director and Clemens Lakner, Associate of the Life Science team will be speaking at SynbioBeta in San Francisco.

all upcoming events

Funding early Innovation

We invest in early stage companies that develop the next generation products, technologies and applications to serve unmet medical needs and improve patient outcomes, as well as new solutions for science driven innovation.

More

Innovative Science.
Strategic Insights.

We invest in innovation to develop novel technologies and products to better serve future healthcare needs, solutions and services for R&D and production of drug therapies, as well as high tech chemicals for sophisticated applications.

More

Strategic Venture Capital.

We work closely with our portfolio companies to optimally position their assets towards strategic partnering.

More

Funding early Innovation

We invest in early stage companies that develop the next generation products, technologies and applications to serve unmet medical needs and improve patient outcomes, as well as new solutions for science driven innovation.

More

Innovative Science.
Strategic Insights.

We invest in innovation to develop novel technologies and products to better serve future healthcare needs, solutions and services for R&D and production of drug therapies, as well as high tech chemicals for sophisticated applications.

More

Strategic Venture Capital.

We work closely with our portfolio companies to optimally position their assets towards strategic partnering.

More